© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
New CRC Screening Recommendations Posted for Adults Aged 45 to 75 Years
October 30, 2020
A draft recommendation statement was published by the United States Preventive Services Task Force stating that screening for colorectal cancer should start at the age of 45, according to a press release from the Task Force Bulletin.
3-Month CAPOX Regimen Appears Less Toxic Than 6-Month Treatment in CRC
October 30, 2020
Results of a randomized phase 3 trial demonstrated that the 3-month regimen of adjuvant combination therapy caused significantly less grade 2 or more peripheral sensory neuropathy than the 6-month regimen as treatment of patients with high-risk stage II colorectal cancer, while not affecting the 3-year disease-free survival rate, according to a report in the Annals of Oncology.
Exploring Current Treatment Options for Patients With HCC
October 30, 2020
Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.
Countless Options to Improve Future Outcomes in Subgroups of Patients With GU Cancers
October 30, 2020
In genitourinary cancers, presentation of subgroup analysis data from large randomized clinical trials demonstrated findings that will change practice for oncologists who treat patients with prostate cancer, bladder cancer, and renal cell carcinoma.
Targeting HRAS Mutations With Investigational Tipifarnib May Hold Promise in Some Tumor Types
October 30, 2020
The high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.
FDA Approves First Companion Diagnostic Test for Expanded EGFR TKIs in NSCLC
October 30, 2020
The FDA has granted approval to the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR tyrosine kinase inhibitors as treatment of patients with EGFR-mutant non–small cell lung cancer, which is the first assay approved for this indication.
Trending News on Targeted Oncology, Week of October 30, 2020
October 30, 2020
Targeted Oncology reviews trending news online for the week of October 30, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.
Immunotherapy Combinations Appear Efficacious in Long-Term Follow-up of Advanced RCC
October 30, 2020
In an interview with Targeted Oncology, Laurence Albiges, MD, PhD, discussed the updated findings for the combination of nivolumab and ipilimumab as treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma.
Crizotinib Activity in MET-Altered Non-Small Cell Lung Cancer Undetermined
October 29, 2020
While the remarkable activity of crizotinib as treatment of patients with ROS1 fusion-positive advanced non–small cell lung cancer was confirmed in a recent systemic review and meta-analysis, the efficacy of this small molecular inhibitor remains unknown in patients with MET-altered disease.
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
October 29, 2020
Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.
FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma
October 29, 2020
The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.
Brander Details Different Therapies and Modalities for Treatment of CLL in the Second Line
October 29, 2020
During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.